MPR21h
FDA Expands Approval of Pluvicto in PSMA-Positive Metastatic CRPC
The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...
Medscape2d
FDA Approves Pluvicto for Earlier Use in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
STAT2d
Emotional whiplash for PTC Therapeutics
Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...
Fierce Pharma5d
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
BioPharma Dive5d
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
Pharmabiz3d
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...
Florida Cancer Specialists & Research Institute Expands Availability Of Advanced Radiopharmaceutical Therapies
Florida Cancer Specialists & Research Institute, LLC (FCS) continues to expand the availability of life-changing and ...
The Pharma Letter2d
Novartis’ Pluvicto gets FDA green light for mCRPC
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...
ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176
Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...
Yahoo Finance7d
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in ...